Lymphoma

Researchers utilized the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to examine the prognostic impact on survival of pre-treatment health-related quality of life parameters for patients with newly diagnosed mantle cell lymphoma.

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

Phase 3 data suggest that concurrent treatment with ibrutinib and venetoclax yielded promising efficacy for patients with relapsed/refractory mantle cell lymphoma.

In this CancerNetwork® OncView™ program, faculty panelist Connie Batlevi, MD, PhD, explains the treatment options in this disease space and discusses a recent drug approval.

The FDA granted priority review to a new drug application for parsaclisib in patients with mantle cell lymphoma and other non-Hodgkin lymphomas.

Connie Batlevi, MD, PhD, detailed important updates in therapies for relapsed/refractory follicular lymphoma in this episode of CancerNetwork’s® podcast.

Yazeed Sawalha, MD, discusses how often autologous stem cell transplant is utilized in patients with mantle cell lymphoma.

Yazeed Sawalha, MD, discusses how socioeconomic factors may impact the completion of autologous stem cell transplant in patients with mantle cell lymphoma, as well as impacting clinical outcomes.

Patients with relapsed or refractory follicular lymphoma who have received 2 prior lines of therapy appear to benefit from treatment with tisagenlecleucel, which was granted a priority review by the FDA.

In an interview with CancerNetwork, Yazeed Sawalha, MD, discussed how socioeconomic factors can affect use of autologous stem cell transplant in multiple myeloma and lead to disparities.

In an interview with ONCOLOGY®, Douglas Braun, CSP, PharmD, RPh, offers a comprehensive review of real-world treatment considerations of umbralisib as therapy for patients with previously treated follicular and marginal zone lymphoma.

As treatment for T-cell non-Hodgkin lymphomas continues to expand, disparities and inequities continue to grow for those within certain racial groups and of a certain socioeconomic status.

Findings from the phase 1 CARBON trial indicated that patients with relapsed/refractory CD19-positive B-cell malignancies may benefit from CTX110 CAR T-cell therapy.

Caron A. Jacobson, MD, MMSC, highlights data supporting the use of CAR T-cell therapy in patients with indolent lymphoma.

After chromosomal abnormality was detected in a single patient treated on the ALPHA 2 trial, the FDA placed a clinical hold on the study pending further information.

Continued overall survival improvement has been observed at landmark time points in patients with mantle cell lymphoma following treatment with autologous hemopoietic stem cell transplant.

Patients with mantle cell lymphoma who experience early relapse after being treated with either intensive or non-intensive frontline therapy are more likely to experience interior survival.

Based on response data from the phase 2 MAGNOLIA trial, the FDA has granted accelerated approval to the Bruton tyrosine kinase inhibitor zanubrutinib to treat patients with relapsed/refractory marginal zone lymphoma.

Epcoritamab monotherapy yielded positive results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and should be studied further, according to investigators.

The combination of zanubrutinib and zandelisib for the treatment of B-cell malignancies may offer patients the opportunity to receive therapy that is not based around chemotherapy.

Zanubrutinib and zandelisib combination appears to be a well-tolerated regimen for the treatment of B-cell malignancies, according to early study results.

Autologous hematopoietic stem-cell transplantation appears to improved survival compared with interferon alfa maintenance therapy for patients with previously untreated mantle cell lymphoma.

Patients with relapsed or regractory B-cell malignancies who were treated with zanubrutinib and zandelisib demonstrated high response rates across several treatment cohorts.

Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.

Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.